NCT06582966CompletedPhase 4
Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
The first study of doxycycline postexposure prophylaxis for cisgender women did not reduce incident STIs likely due to low use of doxycycline. Researchers will conduct a pilot study of once-weekly doxyxycline to prevent bacterial STIs among Kenyan cisgender women using PrEP for HIV prevention.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 30 Aug 2024
- Start date
- 13 Aug 2024
- Primary completion date
- 27 May 2025
- Lead sponsor
- University of Washington
- Diseases
- HIV
- NCT number
- NCT06582966
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 60
- From 13 Aug 2024 to the primary completion date, 27 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current medications which may impact doxycycline metabolism or that are contraindicated with doxycycline, as per the prescribing information. These include systemic retinoids, barbiturates, carbamazepine, phenytoin, and warfarin.
- Prior enrollment in The dPEP Kenya Study
Other illness
- Allergy to tetracycline class
- Active, clinically significant medical or psychiatric conditions that would interfere with study participation, at the discretion of the site investigator or designee.
Other
- Pregnant
- Breastfeeding a child
Who the study is looking for
- Willing and able to give written informed consent
- Age 18-30 years
- Female sex assigned at birth
- HIV-seronegative, according to national HIV testing algorithm
- Has a current prescription for PrEP, \> 1 month, according to the national guidelines of Kenya
Age in the registry: 18 years to 30 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kenya Medical Research Institute (KEMRI) Coordinator of this site? Confirm its status | Kisumu | Kenya | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.